Google-backed AI pharmaceutical company raises $5 billion in funding, doubling the previous round
The current funding round for Isomorphic Labs is co-led by top VCs including Sequoia Capital and Andreessen Horowitz. This round comes only six months after the previous $2.1 billion Series B, with the scale more than doubling. By 2026, total financing in the AI pharmaceutical sector has reached a record high of $23.2 billion, with Anthropic and OpenAI also entering the field.
Isomorphic Labs, an AI pharmaceutical startup under Alphabet, Google’s parent company, has completed a $5 billion Series C funding round, setting a new record for single-round fundraising in the AI drug discovery sector and highlighting the capital market’s strong commitment to AI-driven new drug development tracks.
According to CNBC, Isomorphic Labs announced on Tuesday (November 17) that it had completed a $5 billion Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet. The funds raised will be used to advance AI-driven drug design and development.
This fundraising comes only about six months after Isomorphic Labs’ previous round. The company completed a $2.1 billion Series B round in May this year, with the Series C amount more than doubling that of the previous round. Meanwhile, this funding comes just three and a half months after the company’s founder and former Google DeepMind CEO Demis Hassabis stepped down as DeepMind CEO.
Business Layout: Proprietary Drug Design Engine and Candidate Pipeline
Isomorphic Labs is building a proprietary AI drug design engine and a pipeline of therapeutic candidates. The company states that this system will help develop the next generation of medicines. Its core focus areas include building foundational biology models, deepening the understanding of systemic diseases, and pushing the first therapeutic projects toward clinical trials.
Isomorphic Labs was spun out from DeepMind in 2021 by Demis Hassabis, who has served as CEO since its founding. DeepMind is Google’s AI laboratory, co-founded by Hassabis and acquired by Google in 2014. This year, Hassabis resigned from his role as DeepMind CEO to focus on Isomorphic Labs.
In a statement, Hassabis said: “When we founded Isomorphic, we firmly believed that biology could be understood and modelled at the most fundamental molecular level, and that AI could achieve a step-change acceleration.” He added that this funding round will accelerate the company's progress in building foundational biology models, deepening the understanding of systemic diseases, and advancing the first therapeutic projects toward clinical trials, aiming to deliver tangible impact for patients.
Reports indicate that Isomorphic Labs’ massive funding reflects the surging capital interest in the AI pharmaceutical track. According to transaction data platform Dealroom, total funding for AI drug discovery startups reached $23.2 billion by 2026, a record high.
Several technology giants are also accelerating their layouts in this field. Anthropic announced in June this year that it was launching AI drug discovery projects; in April, OpenAI partnered with Novo Nordisk to jointly explore applications of AI in new drug development.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ-Target shares rise after raising annual sales forecast
Gonka cross-chain bridge attacked, approximately $1.05 million in funds transferred out

Silver Price Forecast: Downtrend deepens as RSI enters oversold territory

